3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
14
Phase 3
10
Phase 2
10
Phase 1
4
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Completed
7
Unknown
3
Recruiting
2
Withdrawn
1
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Interventions
Saline Solution
6
Fentanyl
6
Sodium Chloride
5
Letrozole
5
Dexamethasone
5
Pregabalin
4
Ketamine
4
Goserelin
4
Gemcitabine
4
Bevacizumab
4
Tranexamic Acid
3
Photochemotherapy
3
Pemetrexed
3
Paclitaxel
3
Metformin
3
Leuprolide
3
Docetaxel
3
Cyclophosphamide
3
Carboplatin
3
Capecitabine
3
Acetaminophen
3
ulipristal acetate
2
sodium glycididazole
2
nilotinib
2
liposomal doxorubicin
2
human papillomavirus vaccine, L1 type 16, 18
2
flurbiprofen axetil
2
fludarabine
2
fluciclovine F-18
2
epoetin beta
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Terminated
×
Standard of Care
×
Clear all
NCT01468623
2023-07-19
PROFUSE
Myriad Genetic Laboratories, Inc.
Phase 4
Terminated
51 enrolled